NASDAQ · Biotechnology

INVA (INVA) Stock

$20.51 -2.84% NASDAQ: INVA Healthcare

Valuation

MetricValue
Price$20.51
Market Cap$1.51B
P/E Ratio3.60
P/B Ratio1.24
P/S Ratio3.92
EPS (TTM)$3.30
52-Week High$25.15
52-Week Low$16.52
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE50.72%
ROA6.72%
ROCE13.98%
Gross Margin76.20%
Operating Margin14.85%
Net Margin1.19%
Debt/Equity0.25
Current Ratio14.56

Annual Financials (USD)

Metric20212022202320242025
Revenue$392.0M$331.0M$310.0M$359.0M$425.0M
Operating Profit$375.0M$207.0M$114.0M$167.0M$164.0M
Net Profit$266.0M$214.0M$180.0M$23.0M$271.0M
EPS$2.87$2.37$2.20$0.36$3.30
Op Margin95.7%62.5%36.7%46.5%38.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$926.0M$1.2B$1.2B$1.3B$1.6B
Total Liabilities$400.0M$666.0M$569.0M$610.0M$462.0M
Cash$202.0M$291.0M$194.0M$305.0M$551.0M
Borrowings$395.0M$544.0M$449.0M$451.0M$269.0M

Latest News

INVA: What does Argus have to say about INVA? Argus Research · Jul 15, 2026 Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now? Insider Monkey · Jul 1, 2026 Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform Insider Monkey · Jun 25, 2026 Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally Insider Monkey · Jun 23, 2026 Nortiva Bio Launches to Develop Long-Acting Oral Medicines Business Wire · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$364.0M$202.0M$141.0M$189.0M$197.0M
Investing Cash Flow$42.0M$-57.0M$-67.0M$-64.0M$30.0M
Financing Cash Flow$-454.0M$-122.0M$-76.0M$-15.0M$-5.0M
Net Cash Flow$-45.0M$90.0M$-98.0M$111.0M$246.0M
Free Cash Flow$363.0M$202.0M$141.0M$188.0M$186.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.33
EV / EBITDA7.25
FCF Yield10.87%
Quick Ratio20.07
Interest Coverage9.65
Return 1Y9.96%
Return 3Y60.36%
Return 5Y66.08%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATAI $7.25 +0.97% -8.44 $2.68B 0.00%
CVACCureVac N.V. $4.66 +0.00% 5.69 $1.05B 0.00%
DNTH $104.09 +2.44% -17.99 $4.35B 0.00%
ELVN $60.46 +0.32% -19.91 $4.32B 0.00%
IMTX $8.24 -4.52% -4.98 $1.10B 0.00%

About INVA

INVA is led by CEO Pavel Raifeld, employs 127 people, headquartered in US, publicly traded since 2004.

INVA stock trades at $20.51 with a market capitalization of $1.51B. The stock is valued at a price-to-earnings (P/E) ratio of 3.60, price-to-book of 1.24, price-to-sales of 3.92. Over the past 52 weeks the stock has ranged between $16.52 and $25.15, and currently trades 18.4% below its 52-week high.

On profitability, INVA generates a return on equity (ROE) of 50.72% — well above the market average, a sign of a high-quality business, return on capital employed of 13.98%, an operating margin of 14.85%, a net profit margin of 1.19%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides